62 137

Cited 0 times in

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance

DC Field Value Language
dc.contributor.author김도균-
dc.contributor.author유성환-
dc.contributor.author이관식-
dc.contributor.author이정일-
dc.contributor.author이현웅-
dc.contributor.author정석훈-
dc.date.accessioned2022-03-11T10:56:24Z-
dc.date.available2022-03-11T10:56:24Z-
dc.date.issued2022-01-
dc.identifier.issn0163-2116-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188062-
dc.description.abstractBackground/aims: We investigated the efficiency of the indirect ratio of anti-HBc IgG at predicting HBsAg seroclearance in patients with nucleos(t)ide analogue (NA)-induced HBeAg seroclearance. Methods: We performed a retrospective study that included 366 chronic hepatitis B patients (March 2007 to December 2016) at a single tertiary hospital. These patients were HBsAg seropositive, and experienced NA-induced HBeAg seroclearance. The indirect ratio of light absorbance of anti-HBc IgG levels were measured with chemiluminescent microparticle immunoassay using the Architect Anti-HBc assay (Abbott Laboratories, IL, USA) as a qualitative method prior to antiviral therapy. We calculated the cumulative incidences of HBsAg seroclearance based on the anti-HBc IgG levels. Results: After a 10-year follow-up, 48 patients experienced HBsAg seroclearance (13.1%). Thirty-three of 179 patients who had an indirect ratio of light absorbance of anti-HBc IgG < 11 RLU (relative light unit) showed HBsAg seroclearance (18.4%); 15 of 187 patients who had an indirect ratio of light absorbance of anti-HBc IgG ≥ 11 RLU showed HBsAg seroclerance (8.0%) (p = 0.003). In multivariate analysis, age, and ALT at the time of HBeAg seroclearance were predictors of HBsAg seroclearance. Especially, the relative risk of HBsAg seroclearance in patients with baseline anti-HBc IgG levels < 11 RLU was 2.213 (95% CI, 1.220-4.014), compared to that in patients with higher levels of anti-HBc IgG at baseline (p = 0.009). Conclusion: Using an indirect method for anti-HBc IgG levels, baseline anti-HBc IgG levels (< 11RLU), age (≥ 50 years), and ALT (≥ 40 IU/L) might be associated with HBsAg seroclearance in patients with NA-induced HBeAg seroclearance.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherSpringer Science + Business Media-
dc.relation.isPartOfDIGESTIVE DISEASES AND SCIENCES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents / therapeutic use-
dc.subject.MESHFemale-
dc.subject.MESHHepatitis B Antibodies / blood*-
dc.subject.MESHHepatitis B Core Antigens / immunology*-
dc.subject.MESHHepatitis B e Antigens / immunology*-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHepatitis B, Chronic* / immunology-
dc.subject.MESHHumans-
dc.subject.MESHImmunoglobulin G / blood*-
dc.subject.MESHLiver Function Tests / methods-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNucleosides / therapeutic use*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSeroconversion / drug effects-
dc.subject.MESHSerologic Tests / methods-
dc.subject.MESHTreatment Outcome-
dc.titleAnti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Laboratory Medicine (진단검사의학교실)-
dc.contributor.googleauthorSaein Kim-
dc.contributor.googleauthorSunghwan Yoo-
dc.contributor.googleauthorJung Il Lee-
dc.contributor.googleauthorSora Kim-
dc.contributor.googleauthorHye Young Chang-
dc.contributor.googleauthorDokyun Kim-
dc.contributor.googleauthorSeok Hoon Jeong-
dc.contributor.googleauthorKwan Sik Lee-
dc.contributor.googleauthorHyun Woong Lee-
dc.identifier.doi10.1007/s10620-021-06845-2-
dc.contributor.localIdA04891-
dc.contributor.localIdA05883-
dc.contributor.localIdA02666-
dc.contributor.localIdA03122-
dc.contributor.localIdA03292-
dc.contributor.localIdA03619-
dc.relation.journalcodeJ00737-
dc.identifier.eissn1573-2568-
dc.identifier.pmid33517556-
dc.subject.keywordHepatitis B core antigen-
dc.subject.keywordHepatitis B e antigen-
dc.subject.keywordHepatitis B surface antigen-
dc.subject.keywordHepatitis B virus-
dc.contributor.alternativeNameKim, Dokyun-
dc.contributor.affiliatedAuthor김도균-
dc.contributor.affiliatedAuthor유성환-
dc.contributor.affiliatedAuthor이관식-
dc.contributor.affiliatedAuthor이정일-
dc.contributor.affiliatedAuthor이현웅-
dc.contributor.affiliatedAuthor정석훈-
dc.citation.volume67-
dc.citation.number1-
dc.citation.startPage321-
dc.citation.endPage328-
dc.identifier.bibliographicCitationDIGESTIVE DISEASES AND SCIENCES, Vol.67(1) : 321-328, 2022-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.